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cense. httpAbstract Objective: Primary objective was to verify whether breast cancer patients aged less than
40 years at diagnosis have poorer prognosis than older patients. Secondary to assess prognostic fac-
tors inﬂuencing disease free survival.
Methods: 941 women were diagnosed with non-metastatic breast cancer at NCI, Cairo in 2003.
Epidemiologic, clinico-pathological characteristics, treatment modalities and disease free survival
were compared among the two age groups. Prognostic factors were evaluated for association with
disease-free survival.
Results: One hundred-eighty-one patients (19.2%) were younger than 40 years and 760 (80.8%)
were older. Older women presented with higher rates of comorbidities and younger women pre-
sented with more hormone non-responsive tumors. Young women presented with larger tumors
pT4 = 13.8% compared to 8.6% in older women, yet not signiﬁcant. Young women were treated
with more conservative surgery, more adjuvant chemotherapy and radiotherapy while older women
with more radical mastectomies and more hormonal treatment. Recurrence rates were signiﬁcantly
higher among young women 44.2% compared to 34.5% in older women. Five year disease free364 1772.
(N.H. Alieldin).
e National Cancer Institute,
g by Elsevier
ng by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
://dx.doi.org/10.1016/j.jnci.2013.08.005
24 N.H. Alieldin et al.survival in young women was 38.9%± 4.6% compared to 48.6%± 2.5% with adjusted hazard
ratio of 1.22 95% CI (0.91–1.64), p= 0.19. Multivariate analyses identiﬁed positive axillary lymph
nodes (pN2-pN3), larger tumor size (pT3-pT4), hypertension, lobular carcinoma type and lack of
adjuvant systemic treatment as independent factors associated with poor DFS.
Conclusion: Young women were not found to have poorer prognosis, yet they presented with more
ER negative tumors. Most of women presented with advanced stage and young women had higher
recurrence rates.
ª 2013 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
Open access under CC BY-NC-ND license.Introduction
Among women in Egypt, breast cancer is a challenging health
problem coming on top of all malignancies [1] with a poor out-
come compared to international ﬁgures [2]. Many studies
showed that age at diagnosis of breast cancer in Arab countries
is a decade younger than that in Western countries [3–5]. In the
US median age at presentation for breast cancer is 61 years [5],
compared to 50–54 years in Egypt [1]. A 10-year survey of
breast cancer treatment at the United States showed that
6.4–7.8% of women are diagnosed younger than 40 years of
age [6]. Several studies investigating breast cancer in young wo-
men have shown that it is more aggressive, with higher
mortality and recurrence rates compared with older women
[3,7–9]. Chung and colleagues [8] have found that women
who were diagnosed with invasive breast cancer at 40 years
of age and younger had a poor 5 year disease free survival of
60.8% second only to women older than 80 years of age.
Though a population-based study in Switzerland showed that
young women presented with larger tumors and more aggres-
sive tumors, it found no effect of age on survival [10]. Results
of a study in 1992 in Saudi Arabia and another study in 2004 in
Singapore did not report an adverse effect of age on survival
[11,12]. A recent study in Japan aimed at identifying the prog-
nostic value of age in premenopausal women younger than
40 years of age, found that age at diagnosis was not an inde-
pendent prognostic factor on survival [13]. Although the nega-
tive prognostic impact of young age has been substantiated in
numerous studies, the mystery of young age at diagnosis has
not been resolved in Egypt. The primary aim of the present
study is to verify whether breast cancer patients aged less than
40 years old at diagnosis have poorer prognoses than those
aged 40 years or more. The secondary objective is to assess
prognostic factors inﬂuencing disease free survival in patients
with breast cancer.
Patients and methods
Patients and treatment
From the database of cancer registry system at National Can-
cer Institute Hospital, Cairo, Egypt, women who were diag-
nosed with primary breast cancer in the period between
January and December 2003 with stage I–III disease were in-
cluded. The medical records of the patients included in the
study were reviewed. Information derived from the database
and medical records included epidemiologic, clinical and histo-
logical variables. Epidemiologic variables included age;
residence, and marital status. Age was dichotomized (younger
than 40 years and 40 years of age and older). Women youngerthan 40 years of age were grouped together, as they represent a
special high-risk population. Clinicopathologic data included
menopausal status, family history of breast cancer; history of
diabetes mellitus, hypertension, laterality of the lesion, patho-
logic types, pathologic grade, T stage (primary tumor), N stage
(regional lymph node); estrogen receptor (ER) and progester-
one receptor (PR) status; operative procedures; radiation ther-
apy; adjuvant systemic therapy (chemotherapy and hormonal
therapy).
In all cases, T and N stages were assessed according to the
UICC TNM classiﬁcation (6th edition). ER and PR expression
were determined as positive or negative by enzyme immunoas-
say or immunohistochemistry (IHC).
Regular schedule of patients’ follow up at NCI, Cairo is
every 3–6 months during the ﬁrst 5 years and every 6–
12 months from the 5th to 10th year. Physical examination,
mammography with or without breast ultrasound, chest X-
ray, abdominal ultrasonography and bone scintigraphy are
performed when the patients complain of any symptoms
and/or tumor recurrence is suspected. Approval of Institu-
tional Review Board was achieved for the current study.
Statistical methods
Chi-square test was used to assess differences in clinical and
pathological factors between the two age groups of patients.
A p value 60.05 was considered statistically signiﬁcant. Dis-
ease-free survival (DFS) was deﬁned as the time from surgical
resection to the date of any of the following events: locore-
gional relapse, distant relapse, or death. Locoregional relapse
was deﬁned as the reappearance of cancer in the ipsilateral
breast, chest wall or regional lymph nodes. Distant relapse in-
cluded metastasis in nonvisceral sites (soft-tissue and/or bone)
or visceral (including lung, liver, brain and other organs). DFS
time was estimated by the Kaplan–Meier method and com-
pared among patient subsets using the log-rank test. In univar-
iate analyses, the following prognostic factors were evaluated
for their potential associations with DFS: age at the time of
diagnosis, family history of breast cancer, hypertension and
diabetes (as commonest co-morbidities), pT stage, pN stage,
histological type, histological grade, ER and PR receptor sta-
tus, operative procedure, administration of adjuvant systemic
therapy and radiation therapy. Multivariate analysis of poten-
tial prognostic factors was performed to generate a Cox pro-
portional hazards model. Multivariate models were created
using age at diagnosis and other variables that either showed
signiﬁcant or borderline association or believed to confound
the effect of other prognostic variables on DFS. All tests were
two-tailed, with p value set signiﬁcant at 0.05 level. The statis-
tical software SPSS version 17.0 (SPSS, Inc., Chicago, IL,
USA) was used for all statistical analyses.
Table 1 Epidemiologic and clinico-pathologic characteristics of women with primary breast cancer diagnosed in 2003, at NCI, Cairo
University.
Characteristic All women
n= 941 (%)
Young women
<40 years
n= 181 (%)
Older women
P40 years
n= 760 (%)
p value
Patient characteristics 100 19.2 80.8
Marital status
Single 1.2 2.8 0.8
Married 98.1 97.2 98.3 0.12
Divorced 0.3 0 00.4
Widowed 0.4 0 0.5
Residence
MCA 72.6 66.3 74.1
Middle Egypt 10.5 13.3 9.9
Upper Egypt 2.7 1.7 2.9 0.12
Delta & North Coast 10.9 13.8 10.3
Suez canal, Sinai & others 3.3 5.0 2.9
History of:
Familial breast cancer 3.7 2.8 3.9 0.45
Diabetes mellitus 9.8 1.7 11.7 <0.001
Hypertension 9.7 1.7 11.6 <0.001
Tumor characteristics
Laterality
Right 44.2 49.1 43.0
Left 50.9 47.0 51.8 0.38
Bilateral 1.4 0.6 1.6
Unknown 3.5 3.3 3.6
Pathology
IDC 80.0 83.4 79.2
ILC 7.8 6.6 8.0 0.55
Others 4.1 1.7 4.8
Unknown 8.1 8.3 8.0
Grade
1 2.2 1.1 2.5
2 69.4 70.7 69.1 0.71
3 13.5 13.8 13.4
No grading 14.9 14.4 15.0
pT Stage
0 0.2 0.6 0.1
1 12.4 13.3 12.2
2 42.6 39.2 43.4 0.21
3 19.3 16.6 20.0
4 9.6 13.8 8.6
Unknown 15.8 16.6 15.7
pN Stage
0 24.2 24.3 24.2
1 24.2 23.2 24.5
2 20.8 22.7 20.4 0.97
3 16.4 16.0 16.4
Unknown 14.3 13.8 14.5
TNM stage
0 0.2 0.6 0.1
I 4.6 6.1 4.2
II 35.4 32.6 36.1 0.55
III 47.0 48.6 46.6
Unstaged# 12.9 12.2 13.0
Estrogen receptors
Negative 23.8 33.7 21.4
Positive 41.8 38.7 42.5 0.008
Unknown 34.4 27.6 36.1
Progesterone receptors
Negative 28.1 37.0 25.9
Positive 36.5 34.8 37.0 0.006
Unknown 35.4 28.2 37.1
(continued on next page)
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Table1 (continued)
Characteristic All women
n= 941 (%)
Young women
<40 years
n= 181 (%)
Older women
P40 years
n= 760 (%)
p value
Treatment characteristic
Surgery
MRM 70.8 66.3 71.8
Conservative surgery 16.2 20.4 15.3 0.22
Unknown 13.0 13.3 12.9
Adjuvant chemotherapy
Yes 66.7 77.9 64.1
No 8.6 1.7 10.3 < 0.001
Unknown 24.7 20.4 25.7
Adjuvant hormonal treatment
Yes 40.1 33.7 41.6
No 34.6 42.0 32.9 0.05
Unknown 25.3 24.3 25.5
Adjuvant radiotherapy
Yes 60.0 68.5 58.0
No 22.4 13.8 24.5 0.006
Unknown 17.6 17.7 17.5
Disease free survival events
All relapse (n= 342) 36.3 44.2 34.5 0.02
Distant relapses (n= 315) 33.5 40.3 31.8 0.03
Locoregional relapses (n= 62) 6.6 7.2 6.4 0.72
# Unstaged patients were not stage IV, but lack either T or N or both stages.
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Patient characteristics
Out of a total of 1128 women diagnosed with primary
breast cancer at the NCI, Cairo, Egypt in 2003, patient with
stage IV, metastatic at presentation, comprised 16.6% of all
women and 941 patients were stage I-III. Of which 181
(19.2%) were less than 40 years at diagnosis (young women),
and 760 (80.8%) were 40 years or more (older women) (Ta-
ble 1). The median age at diagnosis was 49.1 years (range
23–90 years).
Analyses illustrated signiﬁcant differences between age
groups in several patient and tumor characteristics. Older
women were more hypertensive and diabetic. The biologic
characteristics of the tumors in younger women were also sig-
niﬁcantly different from tumor characteristics in older women.
Compared with older women, younger women were more
likely to have negative estrogen receptors, and negative proges-
terone receptors (p value 0.006, and 0.04). Finally, treatment
differed between younger and older women, with younger wo-
men receiving more conservative mastectomies (20.4% versus
15.3%) and less modiﬁed radical mastectomies (MRM)
(66.3% versus 71.8%) than their older female counterparts,
yet not signiﬁcant. On the other hand strategy in young women
is toward adjuvant chemotherapy and adjuvant radiotherapy
(77.9% versus 64.1% and 68.5% versus 58%, respectively) as
compared to older women. Hormonal treatment in the young
group was signiﬁcantly lower than the old group. Although
young women presented with larger tumor size pT4 = 13.8%
compared to 8.6% in older women, the absolute difference
was small and not signiﬁcant. Patient, tumor, and treatment
characteristics of the two groups are summarized in Table 1.During a median follow-up of 23 months (range 1–
128 months), 342 patients (36.3%) experienced recurrence
events (distant relapse 33.5% and locoregional relapse
6.6%). Recurrence events mainly distant relapses were signiﬁ-
cantly higher among young women than older women. The 3,
5 and 10-year disease free survival in the whole study group
was 60.1 ± 2.0%, 46.4 ± 2.2% and 35.1 ± 2.5%.
Univariate analyses
For breast cancer patients treated at NCI, Cairo, univariate
analyses showed that signiﬁcant adverse factors associated
with DFS included higher T stage (pT2–4), positive lymph
nodes (pN1–3), grade II + III, negative ER status, absence
of adjuvant systemic therapy and receiving adjuvant radiother-
apy. Age was not found to impact signiﬁcantly DFS despite
the fact that 5 year DFS in older women was 10% higher than
younger women and hazard of relapse in young women is 23%
higher than old women (crude hazard ratio 1.23 (0.96–1.58))
(Table 2 and Figs. 1–4).
Multivariate analyses
In the present study for all ages, multivariate analyses identi-
ﬁed positive axillary lymph nodes (pN2–pN3), larger tumor
size (pT3–pT4), hypertension, tumor histopathology (lobular
carcinomas) and lack of adjuvant systemic treatment as inde-
pendent factors associated with poor DFS (Table 2). Age,
represented as either a categorical or a continuous variable,
was not an independent prognostic factor in multivariate anal-
yses. The negative impact of prognostic factors on DFS is as
follows: hypertension (hazard ratio HR 1.8, 95% CI (1.2–
2.63)), pN2 (HR 2.09, 95% CI (1.38–3.19)), pN3 (HR 4.15,
Table 2 Univariate and multivariate analyses of prognostic factors associated with disease free survival in women with primary breast
cancer diagnosed in 2003, at NCI, Cairo University.
5 years
DFS ± SE
Univariate analysis Multivariate analysis
cHR (95% CI) p value aHR (95% CI) p value
Age
P40 years 48.6 ± 2.5 1 1
<40 years 38.9 ± 4.6 1.23 (0.96–1.58) 0.10 1.22 (0.91–1.64) 0.19
Hypertension
No 46.9 ± 2.3 1 1
Yes 42.7 ± 7.2 1.29 (0.92–1.81) 0.13 1.8 (1.2–2.63) 0.003
Tumor pathology
IDC 47.7 ± 2.4 1 1
ILC 37.2 ± 7.8 1.33 (0.92–1.92) 0.14 1.79 (1.20–2.68) 0.005
Grade of tumor
I 74.1 ± 16.0 1 1
II + III 46.4 ± 2.3 3.10 (0.99–9.63) 052 3.1 (0.66–14.3) 0.15
Axillary lymph nodes
Negative 69.4 ± 3.2 1 1
1–3 +ve (N1) 52.3 ± 4.4 1.66 (1.66–2.37) 0.006 1.47 (0.96–2.27) 0.08
4–9 +ve (N2) 35.8 ± 4.6 2.96 (2.11–4.17) <0.001 2.09 (1.38–3.19) 0.001
P10 +ve (N3) 12.1 ± 3.8 5.50 (3.93–7.87) <0.001 4.15 (2.69–6.41) <0.001
pT Stage
T1 72.1 ± 5.5 1 1
T2 49.3 ± 3.1 1.92 (1.27–2.91) 0.002 1.49 (0.95–2.33) 0.08
T3 34.6 ± 4.8 2.71 (1.74–4.21) <0.001 1.90 (1.18–3.07) 0.009
T4 19.3 ± 5.6 3.86 (2.39–6.22) <0.001 2.21 (1.29–3.79) 0.004
Hormone receptors
ER +ve 47.7 ± 2.9 1 1
ER ve 35.5 ± 3.8 1.3 (1.03–1.64) 0.03 1.45 (0.93–2.26) 0.09
PR +ve 46.7 ± 3.1 1 1
PR ve 37.4 ± 3.6 1.2 (0.95–1.51) 0.12 1.34 (0.90–2.00) 0.15
Surgery
Breast conservation 52.3 ± 6.4 1 1
MRM 45.1 ± 2.4 1.36 (0.96–1.92) 0.09 1.26 (0.84–1.87) 0.26
Adjuvant treatment
Chemotherapy 45.6 ± 2.5 1 1
No chemotherapy 39.7 ± 6.1 1.55 (1.13–2.1) 0.007 3.97 (2.66–5.94) <0.001
Hormonal treatment 58.4 ± 2.9 1 1
No hormones 24.3 ± 3.2 2.66 (2.13–3.22) <0.001 3.75 (2.67–5.27) <0.001
No Radiotherapy 67.1 ± 4.0 1
Radiotherapy 39.7 ± 2.6 1.88 (1.37–2.43) <0.001 1.26 (0.87–1.83) 0.22
SE, standard error; CI, Conﬁdence interval; cHR, crude hazard ratio; aHR, adjusted hazard ratio for; age, tumor grade, pathology type, tumor
size, nodal stage; ER and PR receptor status, type of surgery, and adjuvant treatment.
Age at diagnosis in women with non-metastatic breast cancer 2795% CI 2.69–6.41)), pT3 (HR 1.90 95% CI (1.18–3.07)), pT4
(HR 2.21 95% CI (1.29–3.79)), ILC (HR 1.79 95% CI
(1.20–2.68)), no adjuvant chemotherapy (HR 3.97 95% CI
(2.66–5.94)) and no adjuvant hormonal treatment (HR 3.75
95% CI (2.67–5.27)). Though insigniﬁcant, negative ER and
PR status increases the likelihood of relapses by 45% and
34%, respectively.
Discussion
Age at diagnosis of breast cancer varies considerably among
different populations. In the current study that involved
operable breast cancer patients diagnosed in 2003 at NCI,
Cairo, median age at diagnosis was 49 years, and women
younger than 40 years represented 19.2% in contrast to a Saudi
study published in 2007 [14] where women 40 years or younger
comprised 33.3% of operable breast cancer patients with amedian age of 45 years. In the United States, a large retrospec-
tive cohort study of 243,012 breast cancer patients diagnosed
between 1988 and 2003, showed that only 6.4% were younger
than 40 year old [15]. This disparity is attributed to differences
in population structure with more young population in Egypt
and Saudi Arabia.
The distinction between young and ‘very young’ premeno-
pausal patients is unclear but most investigators who chose
to dichotomize their analysis used an age limit of 35–40 years
[16]. With different age limits many studies reported young age
as an independent adverse prognostic factor in breast cancer
with more aggressive presentation, high mortality and high
recurrence rates [7–9], while others were not in agreement that
young onset breast cancer is associated with poor prognosis
[10–12]. Women younger than 40 years in the current study
showed a slight (22%), but non-signiﬁcant increase in the haz-
ard of relapse compared to older women, (adjusted
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Figure 1 Disease free survival curves in breast cancer patients
younger than 40 years and 40 years or older.
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Figure 3 Disease free survival curves in breast cancer patients
according to (pN) pathologic node stage.
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Figure 4 Disease free survival curves in breast cancer patients
according to tumor pathology.
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Figure 2 Disease free survival curves in breast cancer patients
according to (pT) pathologic tumor stage.
28 N.H. Alieldin et al.HR= 1.22, 95% CI (0.91–1.64), p= 0.19). In spite of the
aggressive treatment received by our young age group (more
adjuvant chemotherapy and radiotherapy), relapse rates either
systemic or loco-regional were signiﬁcantly higher in young
than old women. In the present study and after 10 years of
diagnosis, relapse rate was 44.2% in young women compared
to 34.5% in older women. The higher rate of relapse in the
young group could be explained by larger tumor size at presen-
tation and more negative hormone receptors. Also it could be
explained by more conservative surgical treatment and less
adjuvant hormonal treatment in young women. Elkum et al.
[14] using 40 years and younger as an age limit reported a sig-
niﬁcant increase in the risk of relapse by 51% (HR= 1.51,
95% CI (1.03–2.23), p value = 0.035) among young women.
Anders et al. [17] reported worse prognosis when breast cancer
diagnosis is before age of 40 years accounting for patient,
pathologic and treatment characteristics (RR = 1.6,
P= 0.009).In a Japanese study [13] comparing disease free survival in
women younger than 35 years and those 35–39 years, after a
median follow-up of 80 months (range 5–186) months,
35.5% of all patients experienced DFS events. The discrepancy
in relapse rate between Egyptian and Japanese women younger
than 40 years is supported by the low 5 year DFS in the Egyp-
tian patients (38.9%) compared to 70–73% among Japanese
women [13]. Also 5-year DFS among Saudi women 40 years
and younger was higher than our study (77.4%) [14]. The
exceptionally high rate of relapses in Egyptian patients regard-
less of age is related to more positive node status (median of
pN2) at presentation compared to median of pN0 in Japanese
women [13] and a median of pN1 in Saudi women [14].
Although the Japanese study did not conﬁrm the adverse role
of age in premenopausals, the unpublished data conﬁrm that
breast cancer patients aged less than 40 years have poorer
DFS than those aged 41–49 years (5-year DFS: 79 vs. 86%,
p= 0.04) [13]. In spite of the low estimate of 5 year DFS
(46.4%) in the present study for the whole study group, it
was superior to a study conducted at National Cancer Institute
Age at diagnosis in women with non-metastatic breast cancer 29of Mexico which shows a lower estimate for 5 year DFS (less
than 20%) [18]. Advanced tumor size and more than 85% po-
sitive nodes at presentation in NCI, Mexico explained this
poor ﬁgure.
Also an MD dissertation (unpublished) carried out at NCI,
Cairo, 2006, that compared DFS in 3 study periods (1990,
1995 and 2000) in women with operable breast cancer showed
that 5 year DFS across the 3 periods was 22%, 48%, and 45%.
The 5 year DFS for young women (635 years) in this study
was 32% compared to 40% in older women, HR= 1.24 and
p= 0.13. At NCI, Cairo, effect of age on prognosis did not
seem to be changed as compared to the present study and
the apparent improvement in survival may not mirror
improvement or change in treatment strategy but rather stage
migration.
In agreement with the present study van de Vijver et al. [19]
revealed that age was not an independent prognostic factor,
while gene-expression proﬁle was a signiﬁcant predictor of dis-
ease outcome in younger women with breast cancer. Several
studies supported the conclusion that age itself had no inﬂu-
ence on the prognosis but association of poor prognosis with
young age at diagnosis is explained by higher proportion of
aggressive tumors in younger women in terms of higher T
stage, positive lymph nodes, endocrine non-responsiveness,
high grade and high proliferating fraction [7,9,20–21].
Secondary objective in this study is to ﬁnd other prognostic
factors associated with poor prognosis. Though young age was
not found to be an adverse independent prognostic factor for
DFS, being hypertensive, with large tumor size, positive nodal
status, invasive lobular carcinoma, and receiving no adjuvant
systemic treatment was adversely and independently associated
with disease free survival. Negative ER hormonal receptor sta-
tus showed a tendency to adversely affect DFS (adjusted
HR= 1.45 (0.93–2.26), p= 0.09). In univariate analysis only,
patients who were treated with radiotherapy and radical sur-
gery had signiﬁcantly worse DFS. These ﬁndings reﬂect the
signiﬁcantly higher proportion of positive axillary lymph
nodes and advanced stage in those patients. Axillary positive
nodes in women with primary breast cancer and in many stud-
ies represent an independent poor prognostic parameter across
all age strata. This ﬁnding is supported in the present study
(data not shown).
In support to our ﬁndings, recent studies showed that the
presence of comorbidities as hypertension and type II diabetes
could increase the risk of recurrence and mortality among wo-
men with breast cancer [22–23]. A study conducted on 2389
women with stage I and II invasive breast cancer who were
diagnosed and treated at the M.D. Anderson Cancer Center
between 1985 and 2000 found hypertension (HR 1.22; 95%
CI 0.99–1.49) to be statistically signiﬁcant and a potential
prognostic factor for disease-free survival and overall survival.
The study suggests that co-morbid conditions like hyperten-
sion could account for the racial disparities that exist when
comparing breast cancer survival rates. However future studies
should investigate this relationship further [22].
Previous studies have identiﬁed axillary lymph node status,
hormone receptors and HER2 status, tumor size, histological
grade, operative procedure, radiation therapy, adjuvant
systemic therapy, and age, 35 years or 40 years as independent
prognostic factors in patients with breast cancer [9–
10,14,24,25].In conclusion, our results did not show a signiﬁcant adverse
effect on DFS for young age at diagnosis. However, the inde-
pendent factors associated with poor DFS included hyperten-
sion, positive axillary lymph nodes (pN2–pN3), tumor size
(pT3-pT4), lobular carcinoma type and lack of adjuvant
systemic therapy. Non responsive hormone receptors differ
considerably between the two age groups. An important ﬁnd-
ing is the advanced stage at presentation for all ages, and the
exceptionally high recurrence rate for the young age group.
Preventive and treatment strategies for breast cancer in Egypt
should be extensively revised with tremendous concern for
nationwide screening programs for breast cancer.
Conﬂict of interest
The contents of this manuscript have not been copyrighted or
published previously.
The contents of this manuscript are not now under consid-
eration for publication elsewhere.
The contents of this article will not be copyrighted, submit-
ted or published elsewhere while accepted by Cancer Letters.
There are no directly related manuscripts or abstracts, pub-
lished or unpublished by any author of this article.
No ﬁnancial support or incentive has been provided for this
article.
References
[1] The National Cancer Registry Program of Egypt. Reports and
Statistics: Aswan, Damietta & El-Minia. [online]. Available at:
http://www.cancerregistry.gov.eg/reports.aspx [accessed May,
2013].
[2] Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin
DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality
Worldwide. IARC CancerBase No. 10 .Lyon, France:
International Agency for Research on Cancer [online].
Available from: http://globocan.iarc.fr/factsheets; 2010.
[3] El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem
ZK, Geara FB, et al. Effects of young age at presentation on
survival in breast cancer. BMC Cancer 2006;6:194.
[4] El Saghir NS, Khalil MK, Eid T, El Kinge AR, Charafeddine
M, Geara F, et al. Trends in epidemiology and management of
breast cancer in developing Arab countries: a literature and
registry analysis. Int J Surg 2007;5(4):225e33.
[5] National Cancer Institute: Surveillance, Epidemiology, and End
Results. SEER Cancer Statistics Review 1975–2010. Available:
http://seer.cancer.gov/csr/1975_2010/results_single/
sect_01_table12_2pgs.pdf [accessed May, 2013].
[6] Bland KI, Menck HR, Scott-Conner CE, Morrow M,
Winchester DJ, Winchester DP. The National Cancer
Database 10-year survey of breast carcinoma treatment at
hospitals in the United States. Cancer 1998;83:1262–73.
[7] Zabicki K, Colbert JA, Dominguez FJ, Gadd MA, Hughes KS,
Jones JL, et al. Breast cancer diagnosis in women 40 versus 50
to 60 years: increasing size and stage disparity compared with
older women over time. Ann Surg Oncol 2006;13(8):1072–7.
[8] Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women
with breast carcinoma have a poorer prognosis than older
women. Cancer 1996;77:97–103.
[9] Nixon AJ, Neuburg D, Hayes DF, Gelman R, Connolly JL,
Schnitt S, et al. Relationship of patient age to pathologic
features of the tumor and prognosis for patients with stage I and
stage II breast cancer. J Clin Oncol 1994;12:888–94.
30 N.H. Alieldin et al.[10] Rapiti E, Fioretta G, Verkooijen HM, Vlastos G, Schafer P,
Sappino AP, et al. Survival of young and older breast cancer
patients in Geneva from 1990 to 2001. Eur J Cancer
2005;41:1446–52.
[11] Al-Idrissi HY, Ibrahim EM, Kurashi NY, Sowayan SA. Breast
cancer in a low risk population. The inﬂuence of age and
menstrual status on disease pattern and survival in Saudi
Arabia. Int J Cancer 1992;52:48–51.
[12] Chia KS, Du WB, Sankaranarayanan R, Sankila R, Wang H,
Lee J, et al. Do younger female breast cancer patients have a
poorer prognosis? Results from a population-based survival
analysis. Int J Cancer 2004;108:761–5.
[13] Yoshida M, Shimizu C, Fukutomi T, Tsuda H, Kinoshita T,
Akashi-Tanaka S, et al. Prognostic factors in young Japanese
women with breast cancer: prognostic value of age at diagnosis.
Jpn J Clin Oncol 2011;41(2):180–9.
[14] Elkum N, Dermime S, Ajarim D, Al-Zahrani A, Alsayed A,
Tulbah A, et al. Being 40 or younger is an independent risk
factor for relapse in operable breast cancer patients: the Saudi
Arabia experience. BMC Cancer 2007;7:222.
[15] Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N,
Margenthaler JA. Elevated breast cancer mortality in women
younger than age 40 years compared with older women is
attributed to poorer survival in early-stage disease. J Am Coll
Surg 2009;208(3):341–7.
[16] Aebi S, Castiglione M. The enigma of young age. Ann Oncol
2006;17(10):1475–7.
[17] Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast
cancer before age 40 years. Semin Oncol 2009;36:237–49.
[18] Stankov A, Bargallo-Rocha JE, Silvio AN˜, Ramirez MT,
Stankova-Ninova K, Meneses-Garcia A. Prognostic factorsand recurrence in breast cancer: experience at the national
cancer instituteof Mexico. ISRN Oncol 2012;2012:825258.
[19] van de Vijver MJ, He YD, Van’t Veer LJ, Dai H, Hart AA,
Voskuil DW, et al. A gene-expression signature as a predictor of
survival in breast cancer. N Engl J Med 2002;347:1999–2009.
[20] Kim JK, Kwak BS, Lee JS, Hong SJ, Kim HJ, Son BH, et al.
Do very young Korean breast cancer patients have worse
outcomes? Ann Surg Oncol 2007;14:3385–91.
[21] Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW.
Early-onset breast cancer––histopathological and prognostic
considerations. Br J Cancer 1997;75:1318–23.
[22] Guerra Sandra Lee. Early stage breast cancer and comorbidities:
their impact on breast cancer disease-free survival differences by
ethnicity (January 1, 2010). Texas Medical Center Dissertations
(via ProQuest). Paper AAI1475777. http://digitalcommons.
library.tmc.edu/dissertations/AAI1475777.
[23] Sarkissyan Marianna, Wu Yanyuan, Carlota Marianne,
Vadgama Jaydutt V. Comorbidities are associated with breast
cancer in African-American and Hispanic women. In:
Proceedings of the 103rd Annual Meeting of the American
Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago,
IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8
Suppl.):Abstract nr 5514.
[24] Han W, Kim SW, Park IA, Kang D, Youn YK, Oh SK, et al.
Young age: an independent risk factor for disease-free survival
in women with operable breast cancer. BMC Cancer 2004;4:82.
[25] Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman
J, Valero V, et al. Women age < or =35 years with primary
breast carcinoma: disease features at presentation. Cancer
2005;103:2466–72.
